ArticleJournal of extracellular vesicles2013
Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro.
Article in Journal of extracellular vesicles, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 112 citations in OpenAlex.
- Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Structural dynamics and immunogenicity of the recombinant and outer membrane vesicle-embedded Meningococcal antigen NadA.Nature communications · 2026Article
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Development of a Promising Bivalent Vaccine AgainstExploration (Beijing, China) · 2025Article
- Coated nanoparticles enhance immune efficacy of Helicobacter pylori outer membrane vesicles by activating Th1/Th2/Th17 responses.The Journal of pharmacology and experimental therapeutics · 2025Article
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system.Nature communications · 2025Article
- Intranasal delivery ofHuman vaccines & immunotherapeutics · 2024Article
- Intricate Structure-Function Relationships: The Case of the HtrA Family Proteins from Gram-Negative Bacteria.International journal of molecular sciences · 2024Review
- Genetically surface-modifiedBiotechnology reports (Amsterdam, Netherlands) · 2024Article
- A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis.NPJ vaccines · 2024Article
- Immunohistochemical characterization of the immune cell response during chlamydial infection in the male and female koala (Veterinary pathology · 2024Article
- Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Applied microbiology and biotechnology · 2024Review
- Outer Membrane Vesicle Vaccine Platforms.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Applications of synthetic biology in medical and pharmaceutical fields.Signal transduction and targeted therapy · 2023Review
- OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans.NPJ vaccines · 2023Article
- Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.Applied and environmental microbiology · 2023Article
- A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens.Nature communications · 2023Article
- A bacterial outer membrane vesicle-based click vaccine elicits potent immune response againstFrontiers in immunology · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOuter membrane vesicles (OMVs) are spheroid particles released by all Gram-negative bacteria as a result of the budding out of the outer membrane. Since they carry many of the bacterial surface-associated proteins and feature a potent built-in adjuvanticity, OMVs are being utilized as vaccines, some of which commercially available. Recently, methods for manipulating the protein content of OMVs have been proposed, thus making OMVs a promising platform for recombinant, multivalent vaccines development.
methodsChlamydia muridarum DO serine protease HtrA, an antigen which stimulates strong humoral and cellular responses in mice and humans, was expressed in Escherichia coli fused to the OmpA leader sequence to deliver it to the OMV compartment. Purified OMVs carrying HtrA (CM rHtrA-OMV) were analyzed for their capacity to induce antibodies capable of neutralizing Chlamydia infection of LLC-MK2 cells in vitro.
resultsCM rHtrA-OMV immunization in mice induced antibodies that neutralize Chlamydial invasion as judged by an in vitro infectivity assay. This was remarkably different from what observed with an enzymatically functional recombinant HtrA expressed in, and purified from the E. coli cytoplasm (CM rHtrA). The difference in functionality between anti-CM rHtrA and anti-CM rHtrA-OMV antibodies was associated to a different pattern of protein epitopes recognition. The epitope recognition profile of anti-CM HtrA-OMV antibodies was similar to that induced in mice during Chlamydial infection.
conclusionsWhen expressed in OMVs HtrA appears to assume a conformation similar to the native one and this results in the elicitation of functional immune responses. These data further support the potentiality of OMVs as vaccine platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.